Latest filings (excl ownership)
CT ORDER
Confidential treatment order
13 Feb 18
15-12B/A
Securities registration termination (amended)
2 Aug 16
EFFECT
Notice of effectiveness
1 Aug 16
POS AM
Prospectus update (post-effective amendment)
27 Jul 16
EFFECT
Notice of effectiveness
25 Jul 16
15-12B
Securities registration termination
22 Jul 16
25-NSE
Exchange delisting
12 Jul 16
8-K
Termination of a Material Definitive Agreement
12 Jul 16
POS AM
Prospectus update (post-effective amendment)
12 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Jul 16
SC 14D9/A
Tender offer solicitation (amended)
12 Jul 16
SC TO-T/A
Third party tender offer statement (amended)
12 Jul 16
SC 14D9/A
Tender offer solicitation (amended)
6 Jul 16
SC TO-T/A
Third party tender offer statement (amended)
6 Jul 16
SC 14D9/A
Tender offer solicitation (amended)
30 Jun 16
SC TO-T/A
Third party tender offer statement (amended)
29 Jun 16
SC 14D9/A
Tender offer solicitation (amended)
27 Jun 16
SC TO-T/A
Third party tender offer statement (amended)
27 Jun 16
S-8
Registration of securities for employees
15 Jun 16
8-K
Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia
14 Jun 16
SC 14D9
Tender offer solicitation
10 Jun 16
SC TO-T
Third party tender offer statement
10 Jun 16
8-K
Other Events
6 Jun 16
SC14D9C
Written communication relating to third party tender offer
1 Jun 16
SC14D9C
Written communication relating to third party tender offer
1 Jun 16
8-K
U.S. regulatory submission for VYXEOS planned by end of third quarter 2016
31 May 16
DEFA14A
Additional proxy soliciting materials
31 May 16
SC TO-C
Information about tender offer
31 May 16
SC TO-C
Information about tender offer
31 May 16
SC14D9C
Written communication relating to third party tender offer
31 May 16
10-Q
2016 Q1
Quarterly report
10 May 16
DEF 14A
Definitive proxy
28 Apr 16
8-K
Entry into a Material Definitive Agreement
27 Apr 16
8-K
Departure of Directors or Certain Officers
5 Apr 16
424B5
Prospectus supplement for primary offering
24 Mar 16
8-K
Entry into a Material Definitive Agreement
23 Mar 16
S-3MEF
Registration of additional securities for an S-3
23 Mar 16
424B5
Prospectus supplement for primary offering
22 Mar 16
10-K
2015 FY
Annual report
21 Mar 16
Latest ownership filings
SC 13G/A
Celator Pharmaceuticals Inc
15 Feb 17
SC 13G/A
Celator Pharmaceuticals Inc
14 Feb 17
SC 13G/A
Celator Pharmaceuticals Inc
30 Jan 17
SC 13D/A
Celator Pharmaceuticals Inc
15 Jul 16
4
Richard S Kollender
13 Jul 16
4
ASSOCIATES, L.L.C. CDK
12 Jul 16
4
MICHAEL R DOUGHERTY
12 Jul 16
4
NICOLE VITULLO
12 Jul 16
4
JEAN-PIERRE BIZZARI
12 Jul 16
4
Scott Thomas Jackson
12 Jul 16
4
Fred M Powell
12 Jul 16
4
Joseph M Lobacki
12 Jul 16
4
Eric W Roberts
12 Jul 16
4
JOSEPH A MOLLICA
12 Jul 16
4
Scott D Morenstein
12 Jul 16
4
Lawrence David Mayer
12 Jul 16
4
Scott Thomas Jackson
7 Jul 16
4
Fred M Powell
7 Jul 16
4
Fred M Powell
1 Jul 16
4
Fred M Powell
27 Jun 16
4
ASSOCIATES, L.L.C. CDK
22 Jun 16
SC 13D/A
Celator Pharmaceuticals Inc
22 Jun 16
4
Eric W Roberts
22 Jun 16
SC 13D/A
Celator Pharmaceuticals Inc
1 Jun 16
SC 13G
Celator Pharmaceuticals Inc
27 Apr 16
SC 13D/A
Celator Pharmaceuticals Inc
22 Apr 16
4
Lawrence David Mayer
17 Mar 16
SC 13G
Celator Pharmaceuticals Inc
15 Mar 16
SC 13G/A
Celator Pharmaceuticals Inc
16 Feb 16
4
MICHAEL R DOUGHERTY
29 Jan 16
4
Fred M Powell
29 Jan 16
4
Scott Thomas Jackson
29 Jan 16
4
Lawrence David Mayer
29 Jan 16
4
Scott D Morenstein
7 Dec 15
4
ASSOCIATES, L.L.C. CDK
4 Dec 15
4
Scott Thomas Jackson
7 Oct 15
4
Fred M Powell
5 Oct 15
4
Eric W Roberts
2 Oct 15
4
MICHAEL R DOUGHERTY
24 Aug 15
4
MICHAEL R DOUGHERTY
15 Jun 15